AbbVie Inc. $ABBV Shares Purchased by Apollon Wealth Management LLC

Apollon Wealth Management LLC boosted its stake in AbbVie Inc. (NYSE:ABBV) by 6.8% in the first quarter, Holdings Channel.com reports. The fund owned 119,615 shares of the company’s stock after buying an additional 7,638 shares during the quarter. Apollon Wealth Management LLC’s holdings in AbbVie were worth $26,015,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of ABBV. Horizon Advisory Services Inc. purchased a new stake in shares of AbbVie in the 1st quarter valued at about $211,000. Riverbend Wealth Management LLC grew its stake in AbbVie by 7.7% during the 1st quarter. Riverbend Wealth Management LLC now owns 3,853 shares of the company’s stock worth $838,000 after buying an additional 276 shares during the last quarter. Red Door Wealth Management LLC increased its position in AbbVie by 1.7% during the first quarter. Red Door Wealth Management LLC now owns 47,908 shares of the company’s stock worth $10,419,000 after buying an additional 798 shares during the period. Aspire Private Capital LLC increased its position in AbbVie by 13.0% during the first quarter. Aspire Private Capital LLC now owns 9,130 shares of the company’s stock worth $1,986,000 after buying an additional 1,047 shares during the period. Finally, Matrix Asset Advisors Inc. NY lifted its stake in AbbVie by 2.3% in the first quarter. Matrix Asset Advisors Inc. NY now owns 39,175 shares of the company’s stock valued at $8,520,000 after buying an additional 890 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ABBV. Evercore set a $235.00 target price on shares of AbbVie in a research report on Friday, May 15th. Piper Sandler reiterated an “overweight” rating and issued a $298.00 price target on shares of AbbVie in a research report on Tuesday, June 23rd. Wells Fargo & Company set a $260.00 price target on shares of AbbVie in a research note on Monday, June 22nd. Guggenheim restated a “buy” rating and issued a $249.00 price objective on shares of AbbVie in a research note on Friday, May 1st. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $253.81.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said the FDA approved Skyrizi for pediatric use in psoriatic disease, making it the first and only IL-23 inhibitor in the U.S. approved for children six years and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis. The expansion broadens the drug’s addressable market and supports long-term sales growth. Article: SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
• Positive Sentiment: AbbVie’s Apogee Therapeutics acquisition is being viewed favorably by analysts, with Canaccord raising its price target and saying the deal strengthens AbbVie’s long-term growth outlook by adding promising pipeline assets. Article: AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
• Positive Sentiment: AbbVie is also benefiting from broader healthcare sector strength, with shares hitting new highs as investors rotate into defensive large-cap pharma names. Article: Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms
• Neutral Sentiment: AbbVie announced it will host its second-quarter 2026 earnings call on July 31, which is a standard investor update and does not by itself change fundamentals. Article: AbbVie to Host Second-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Commentary pieces also highlighted AbbVie’s recent pediatric label expansions in Europe for Skyrizi and Maviret, reinforcing the company’s shift toward earlier-disease and younger-patient growth opportunities. Article: Will AbbVie’s (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?

AbbVie Stock Performance

Shares of ABBV opened at $251.52 on Monday. The stock has a market capitalization of $444.38 billion, a P/E ratio of 123.90, a P/E/G ratio of 0.77 and a beta of 0.32. AbbVie Inc. has a 1 year low of $181.73 and a 1 year high of $253.35. The company’s fifty day moving average is $215.16 and its two-hundred day moving average is $219.16.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business’s revenue was up 12.4% on a year-over-year basis. During the same quarter last year, the business earned $2.46 EPS. Sell-side analysts predict that AbbVie Inc. will post 14.28 EPS for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. AbbVie’s dividend payout ratio (DPR) is presently 340.89%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.